Replies to post #3672 on Geron Corp (GERN)

[subslover]

Zacks Short Term Rating on Geron Corporation (NASDAQ:GERN)

Britta Smith June 23, 2015


As much as 3 analysts have advised buy on Geron Corporation (NASDAQ:GERN) with an average broker rating of 1.67. Experts at Zacks have given it a short term rating of 2, which means that the investors can Buy for the short term positions. Geron Corporation (NASDAQ:GERN) shares are expected to touch $5.25 in the short term. This short term price target has been shared by 2 analysts. However, the standard deviation of short term price estimate has been valued at 0.35. The target price could hit $6 on the higher end and $5 on the lower end.

The company shares have rallied 42.32% in the past 52 Weeks. On March 13, 2015 The shares registered one year high of $4.49 and one year low was seen on October 13, 2014 at $1.76. The 50-day moving average is $3.91 and the 200 day moving average is recorded at $3.61. S&P 500 has rallied 7.51% during the last 52-weeks.

Geron Corporation (NASDAQ:GERN) rose 3.99% or 0.16 points on Monday and made its way into the gainers of the day. After trading began at $4.02 the stock was seen hitting $4.18 as a peak level and $4.008 as the lowest level. The stock ended up at $4.17. The daily volume was measured at 2,273,996 shares. The 52-week high of the share price is $4.49 and the 52-week low is $1.76. The company has a market cap of $659 million.



Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Companys stem cell assets.